| Name | Title | Contact Details |
|---|
Founded in 2016, Huupe is the first-ever smart basketball hoop. It brings competition and training to basketball enthusiasts and players, including NBA athletes as well as stars from the league who have invested in the company. Huupe`s groundbreaking innovation enables ages eight and up to compete on the court or virtually, learn and improve their skills, track their progress, and more. The appointment of Paul as CTO follows the company`s 400% growth month over month in the past six months this year, with 50% growth in October 2022 alone, and viral popularity on social media.
One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital`s existing pharmacy programs.
Built around a portfolio of recognized brands, Golden Leaf Holdings Incorporate is one of the largest cannabis oil and solution providers in North America. The Company leverages a strong management team with cannabis and food industry experience to complement its expertise in the extracting, refining and selling of cannabis oil, edibles and flower products. The Company has developed a strong consumer brand portfolio (“Golden Brands”) that includes the Golden, Proper, Chalice Farms, Liberty Reach and Jackpot Seaweed brands. In addition to leading branded products, Golden Leaf also maintains a foothold in the Oregon retail dispensary market with its award-winning chain of Chalice Farms retail stores.
Rowan Regional Medical Center is a Salisbury, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.